Literature DB >> 34725042

Identification of BRAF p. V600E-Mutant and Wild-Type by MR Imaging in Pleomorphic Xanthoastrocytoma and Anaplastic Pleomorphic Xanthoastrocytoma.

W Huang1,2, J Cai1,2, N Lin3, Y Xu1,2, H Wang1,2, Z Wu4,2, D Kang1,2.   

Abstract

BACKGROUND AND
PURPOSE: Compared with BRAF p. V600E wild-type pleomorphic xanthoastrocytoma, BRAF p. V600E-mutant pleomorphic xanthoastrocytoma showed a higher survival rate. In this study, we focused on finding preoperative MR imaging differences between BRAF p. V600E mutant and wild-type in pleomorphic xanthoastrocytoma and anaplastic pleomorphic xanthoastrocytoma.
MATERIALS AND METHODS: Twenty-three patients with pathologically confirmed pleomorphic xanthoastrocytoma or anaplastic pleomorphic xanthoastrocytoma in our hospital were retrospectively analyzed from January 2015 to December 2020. They were divided into a BRAF p. V600E-mutant group (including 6 pleomorphic xanthoastrocytomas and 5 anaplastic pleomorphic xanthoastrocytomas) and a wild-type group (including 8 pleomorphic xanthoastrocytomas and 4 anaplastic pleomorphic xanthoastrocytomas). The preoperative MR imaging characteristics of these groups were statistically compared.
RESULTS: The wild-type pleomorphic xanthoastrocytoma group presented with more aggressive conventional and advanced MR imaging features than the mutant pleomorphic xanthoastrocytoma group, including greater mean maximum tumor diameter (3.1 [SD, 0.9] cm versus 1.7 [SD, 0.4 ] cm, P < .05), more frequent heterogeneous contrast enhancement of solid portions (100% versus 0%, P < .001), more obvious peritumoral edema (mean, [2.1 SD, 0.7] cm versus 0.6 [SD, 0.2] cm, P < .01), and lower mean minimum relative ADC (896 [SD, 86] versus 988 [SD, 73], P < .05) and mean relative ADC (1060 [SD, 159] versus 1248 [SD, 116], P < .05) on DWI. However, there was no significant difference in either conventional or advanced MR imaging features between the wild-type anaplastic pleomorphic xanthoastrocytoma group and the mutant anaplastic pleomorphic xanthoastrocytoma group.
CONCLUSIONS: Neurosurgeons should carefully interpret MR images before an operation and select appropriate surgical strategies according to genotype prediction.
© 2021 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34725042      PMCID: PMC8805743          DOI: 10.3174/ajnr.A7324

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  37 in total

1.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.

Authors:  Genevieve Schindler; David Capper; Jochen Meyer; Wibke Janzarik; Heymut Omran; Christel Herold-Mende; Kirsten Schmieder; Pieter Wesseling; Christian Mawrin; Martin Hasselblatt; David N Louis; Andrey Korshunov; Stefan Pfister; Christian Hartmann; Werner Paulus; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2011-01-29       Impact factor: 17.088

Review 2.  MR and CT imaging of 24 pleomorphic xanthoastrocytomas (PXA) and a review of the literature.

Authors:  Ana M Crespo-Rodríguez; James G Smirniotopoulos; Elisabeth J Rushing
Journal:  Neuroradiology       Date:  2007-01-05       Impact factor: 2.804

Review 3.  Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature.

Authors:  Elisabetta Marton; Alberto Feletti; Enrico Orvieto; Pierluigi Longatti
Journal:  J Neurol Sci       Date:  2006-12-26       Impact factor: 3.181

4.  Pleomorphic xanthoastrocytoma in children and adolescents.

Authors:  Amulya A Nageswara Rao; Nadia N Laack; Caterina Giannini; Cynthia Wetmore
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

5.  cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.

Authors:  David N Louis; Pieter Wesseling; Kenneth Aldape; Daniel J Brat; David Capper; Ian A Cree; Charles Eberhart; Dominique Figarella-Branger; Maryam Fouladi; Gregory N Fuller; Caterina Giannini; Christine Haberler; Cynthia Hawkins; Takashi Komori; Johan M Kros; H K Ng; Brent A Orr; Sung-Hye Park; Werner Paulus; Arie Perry; Torsten Pietsch; Guido Reifenberger; Marc Rosenblum; Brian Rous; Felix Sahm; Chitra Sarkar; David A Solomon; Uri Tabori; Martin J van den Bent; Andreas von Deimling; Michael Weller; Valerie A White; David W Ellison
Journal:  Brain Pathol       Date:  2020-04-19       Impact factor: 6.508

6.  Utility of apparent diffusion coefficient ratios in distinguishing common pediatric cerebellar tumors.

Authors:  Barjor Gimi; Kevin Cederberg; Betul Derinkuyu; Lynn Gargan; Kadriye M Koral; Daniel C Bowers; Korgun Koral
Journal:  Acad Radiol       Date:  2012-04-17       Impact factor: 3.173

7.  Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry.

Authors:  Birthe Krogh Rasmussen; Steinbjørn Hansen; René J Laursen; Michael Kosteljanetz; Henrik Schultz; Bente Mertz Nørgård; Rikke Guldberg; Kim Oren Gradel
Journal:  J Neurooncol       Date:  2017-08-31       Impact factor: 4.130

Review 8.  Epidemiologic and molecular prognostic review of glioblastoma.

Authors:  Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-22       Impact factor: 4.254

9.  Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2013-06-12       Impact factor: 4.130

10.  Dabrafenib and trametinib in BRAFV600E mutated glioma.

Authors:  Nicholas F Brown; Thomas Carter; Neil Kitchen; Paul Mulholland
Journal:  CNS Oncol       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.